An open-label, randomized, single intravenous dosing study to investigate the effect of fixed dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)
Loading...
Date
2021
Journal Title
Journal ISSN
Volume Title
Publisher
Research Square
Abstract
Remdesivir is a novel broad-spectrum antiviral therapeutic with activity against several viruses that cause emerging infectious diseases. The purpose of this study is to explore how commonly utilized antiretroviral therapy (tenofovir disoproxil fumarate /lamivudine [TDF/3TC] and atazanavir/ritonavir [ATV/r]) influence plasma and intracellular concentrations of remdesivir.
Description
Keywords
Remdesivir, COVID-19, Ebola, HIV, Atazanavir, Ritonavir, Tenofovir, Lamivudine, Drug-drug interactions
Citation
Walimbwa, S. I., Kaboggoza, J. P., Waitt, C., Byakika-Kibwika, P., D'Avolio, A., & Lamorde, M. (2021). An open-label, randomized, single intravenous dosing study to investigate the effect of fixed dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). https://orcid.org/0000-0002-3825-3260